Prof Philippe Moreau MD
University Hospital of Nantes, France
Philippe Moreau is a Professor of Clinical Hematology and Head of the Translational Research Program in Hematology and Oncology, at the University Hospital of Nantes, France.
He has over 20 years’ experience in clinical hematology and has led many pivotal clinical studies. including with cell therapies. His interests are focused on multiple myeloma (MM) and its treatment with high-dose therapy and novel agents, including cell therapies.
Professor Moreau has been the Chairman of the Intergroupe Francophone du Myélome (IFM) since 2020 and Vice-President of the International Myeloma Society (IMS) since 2019. He has been a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. Professor Moreau has served as the Principal Investigator for many international randomized phase 3 clinical trials evaluating proteasome inhibitors, Immunomodulatory drugs (IMiDs) or CD38 antibodies. He participated in the study of Idecabtagene Vicleucel (Abecma), that received FDA approval in March 2021 as the first genetically modified autologous chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed and refractory MM.
He has authored or coauthored more than 400 peer-reviewed articles that have appeared in high impact factor journals including, the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet, The Lancet Oncology, and Blood.
In 2018 Professor Moreau received the Robert A. Kyle lifetime achievement award.
Professor Moreau obtained his medical degree from the University of Reims, France.
